flupentixol

Trade name: Depixol

Small moleculeexperimental

Melitracen is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol. — Wikipedia

Clinical trial activity

18 trials · 13 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 1994 (NCT00000241)

Timeline

1990s

Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
Jan 1, 1999
Earliest Phase 1 Sponsor(trial)

2010s

Jan 1, 2015
Earliest Phase 3 Sponsor(trial)

Mechanism of action

Dopamine D1 and D2 receptorANTAGONIST
Dopamine D1 and D2 receptor antagonist
- D(2) dopamine receptor (DRD2) ↗
- D(1A) dopamine receptor (DRD1) ↗
- Dopamine D2 receptor
- Dopamine D1 receptor

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21

Mol. weight: 291.44 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

dixeran
fluanxol
flupenthixol
flupenthixol
flupenthixol
flupenthixole
flupenthixole
flupentixol
flupentixol
flupentixol
flupentixol
flupentixol
flupentixol
flupentixol
flupentixol
flupentixol dihydrochloride
flupentixol hcl
flupentixol hydrochloride
flupentixol hydrochloride
flupentixol hydrochloride
flupentixol hydrochloride
flupentixol hydrochloride
flupentixol hydrochloride
flupentixolo
flupentixolo
flupentixolum
flupentixolum
fluxanxol
lc-44
lc-44
melitracen
melitracen
melitracen
melitracen
melitracene
melitracen hcl
melitracen hydrochloride
melitracen hydrochloride
melitracen hydrochloride
melitracen hydrochloride
n-7009
n-7009
n-7009

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06927375	Phase 4	Dec 12, 2024	Jiao Tong University
NCT04898270	Phase 4	Dec 19, 2019	Taichung Veterans General Hospital
NCT03472651	Phase 1	May 7, 2018	Lundbeck
NCT04970667	Phase 4	Jan 1, 2018	Peking University
NCT03205228	Phase 3	Jul 7, 2017	Mahidol University
NCT02660840	Phase 1	Jan 1, 2016	Lundbeck
NCT02723903	Phase 1/Phase 2 (Phase 2)	Dec 1, 2015	Jiao Tong University
NCT02374567	Phase 3	Jan 1, 2015	Gottfried Wilhelm Leibniz Universität Hannover
NCT02307396	Phase 4	Nov 1, 2014	Technical University of Munich
NCT02179931	Phase 1	Jun 1, 2014	Lundbeck
NCT01851863	Phase 4	May 1, 2013	Jiao Tong University
NCT01164059	Phase 4	Feb 1, 2010	German Federal Ministry of Education and Research, University of Bremen
NCT00841230	Phase 4	Feb 1, 2009	University of Antwerp
NCT00000349	Phase 1	Sep 20, 1999	Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA)
NCT00000274	Phase 2	Mar 1, 1997	Columbia University, National Institute on Drug Abuse (NIDA)
NCT00000275	Phase 2	Nov 1, 1996	Columbia University, National Institute on Drug Abuse (NIDA)
NCT00000266	Phase 2	Aug 1, 1994	Columbia University, National Institute on Drug Abuse (NIDA)
NCT00000241	Phase 2	Feb 1, 1994	Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA)

Showing 18 of 18 trials

Page 1 / 1

Organizations

Research & Development (13)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
National Institute on Drug Abuse (NIDA)	Government	5	5	2	1994
Columbia University	Academic/Hospital	3	0	1	1994
Jiao Tong University	Academic/Hospital	3	3	2	2013
Lundbeck	For profit	3	3	1	2014
Friends Research Institute, Inc.	Academic/Hospital	2	0	2	1994
German Federal Ministry of Education and Research	Government	1	0	1	2010
Gottfried Wilhelm Leibniz Universität Hannover	Academic/Hospital	1	1	1	2015
Mahidol University	Academic/Hospital	1	1	1	2017
Peking University	Academic/Hospital	1	1	1	2018
Taichung Veterans General Hospital	Academic/Hospital	1	1	1	2019
Technical University of Munich	Academic/Hospital	1	1	1	2014
University of Antwerp	Academic/Hospital	1	1	1	2009
University of Bremen	Academic/Hospital	1	1	1	2010

13 organizations